相似文献
1
Targeting the B-cell lymphoma/leukemia 2 family in cancer.
J Clin Oncol. 2012 Sep 1;30(25):3127-35. doi: 10.1200/JCO.2011.37.0981. Epub 2012 May 29.
2
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Pathology. 2011 Oct;43(6):525-35. doi: 10.1097/PAT.0b013e32834b1b34.
3
Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Drugs. 2019 Aug;79(12):1287-1304. doi: 10.1007/s40265-019-01163-4.
4
BH3 mimetics to improve cancer therapy; mechanisms and examples.
Drug Resist Updat. 2007 Dec;10(6):207-17. doi: 10.1016/j.drup.2007.08.002. Epub 2007 Oct 24.
5
Why anti-Bcl-2 clinical trials fail: a solution.
Cancer Metastasis Rev. 2014 Mar;33(1):285-94. doi: 10.1007/s10555-013-9450-8.
6
Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer.
Int J Mol Sci. 2021 Mar 11;22(6):2841. doi: 10.3390/ijms22062841.
7
Mimicking the BH3 domain to kill cancer cells.
Oncogene. 2008 Dec;27 Suppl 1(0 1):S149-57. doi: 10.1038/onc.2009.52.
8
Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells.
Blood. 2012 Jun 14;119(24):5807-16. doi: 10.1182/blood-2011-12-400929. Epub 2012 Apr 26.
9
Bcl-2 inhibitors: small molecules with a big impact on cancer therapy.
Cell Death Differ. 2009 Mar;16(3):360-7. doi: 10.1038/cdd.2008.137. Epub 2008 Sep 19.
10
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy.
Clin Cancer Res. 2009 Feb 15;15(4):1126-32. doi: 10.1158/1078-0432.CCR-08-0144.
引用本文的文献
1
Dual-targeted siRubicon delivery strategy triggers hepatocellular lipophagy for mitigating liver steatosis.
Nat Commun. 2025 Aug 12;16(1):7455. doi: 10.1038/s41467-025-61965-x.
2
The role of mitochondria-associated ER membranes in disease pathology: protein complex and therapeutic targets.
Front Cell Dev Biol. 2025 Jun 30;13:1629568. doi: 10.3389/fcell.2025.1629568. eCollection 2025.
3
Cell Death Modalities in Therapy of Melanoma.
Int J Mol Sci. 2025 Apr 8;26(8):3475. doi: 10.3390/ijms26083475.
4
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
5
Homoharringtonine in the treatment of acute myeloid leukemia: A review.
Medicine (Baltimore). 2024 Nov 1;103(44):e40380. doi: 10.1097/MD.0000000000040380.
6
CAR-T cell combination therapies in hematologic malignancies.
Exp Hematol Oncol. 2024 Jul 18;13(1):69. doi: 10.1186/s40164-024-00536-0.
7
Small Molecule Functional Converter of B-Cell Lymphoma-2 (Bcl-2) Suppresses Breast Cancer Lung Metastasis.
ACS Pharmacol Transl Sci. 2024 May 1;7(5):1302-1309. doi: 10.1021/acsptsci.3c00360. eCollection 2024 May 10.
8
AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death.
Cell Death Differ. 2024 Apr;31(4):405-416. doi: 10.1038/s41418-024-01283-9. Epub 2024 Mar 27.
9
In Silico Analysis of Novel Bacterial Metabolites with Anticancer Activities.
Metabolites. 2024 Mar 13;14(3):163. doi: 10.3390/metabo14030163.
10
The Effects of ABT-199 and Dihydroartemisinin Combination on Cell Growth and Apoptosis in Human U937 and KG-1 Cancer Cells.
Asian Pac J Cancer Prev. 2024 Jan 1;25(1):343-350. doi: 10.31557/APJCP.2024.25.1.343.
本文引用的文献
1
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
J Clin Oncol. 2012 Feb 10;30(5):488-96. doi: 10.1200/JCO.2011.34.7898. Epub 2011 Dec 19.
2
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.
3
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.
4
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.
Blood. 2011 Sep 29;118(13):3579-90. doi: 10.1182/blood-2011-03-340364. Epub 2011 Jul 19.
5
Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets.
Blood. 2011 Aug 11;118(6):1663-74. doi: 10.1182/blood-2011-04-347849. Epub 2011 Jun 14.
6
BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation.
Blood. 2011 Jun 30;117(26):7145-54. doi: 10.1182/blood-2011-03-344812. Epub 2011 May 11.
7
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.
J Clin Oncol. 2011 Mar 1;29(7):909-16. doi: 10.1200/JCO.2010.31.6208. Epub 2011 Jan 31.
8
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18.
9
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.
Br J Cancer. 2010 Aug 24;103(5):668-75. doi: 10.1038/sj.bjc.6605736. Epub 2010 Jul 27.
10
Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes.
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12895-900. doi: 10.1073/pnas.0914878107. Epub 2010 Jul 6.
Zotero 插件